𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Usefulness of osteoprotegerin in assessing responses to neridronate treatment in Paget's disease of bone

✍ Scribed by F. M. Ulivieri; L. P. Piodi; G. Marotta; D. Marchelli; C. Commadini; L. Parravicini; C. Verdoia; P. Gerundini

Publisher
Springer Milan
Year
2006
Tongue
English
Weight
94 KB
Volume
7
Category
Article
ISSN
1590-9921

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Use of etidronate (ehdp) in paget's dise
Use of etidronate (ehdp) in paget's disease of bone
✍ C. Conrad Johnston Jr; M. R. A. Khairi; P. J. Meunier πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 382 KB πŸ‘ 1 views

## Abstract Etidronate used in recommended doses (usually 5 mg/kg/day for 6 months) produces symptomatic improvement in approximately 60% of patients. The serum alkaline phosphatase and urinary hydroxyproline are reduced to about 50% of initial values. A sustained remission occurs in many patients